Drug Profile
Research programme: TGF-beta type I receptor inhibitors - In2Gen
Alternative Names: ALK5 inhibitors - In2Gen; IN-1130; TGF-beta type I receptor (ALK5) inhibitors research programme - In2GenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator In2Gen
- Class Imidazoles; Quinoxalines; Small molecules
- Mechanism of Action Activin receptor antagonists; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Connective tissue disorders; Fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in South Korea
- 04 Nov 2017 No recent reports of development identified for preclinical development in Connective-tissue-disorders in South Korea
- 04 Nov 2017 No recent reports of development identified for preclinical development in Fibrosis in South Korea (PO)